Anthrax Vaccine Work Group

David S. Stephens, MD, FIDSA
ACIP Anthrax Vaccine Work Group

Advisory Committee for Immunization Practices
October 24, 2018
ACIP Anthrax Work Group Members

ACIP Members:  David Stephens, Chair;  Robert L. Atmar; Sharon Frey

Ex Officio Members: Judy Hewitt (NIH); Amanda Zarrabian (BARDA); Alexandra Worobec (FDA); Eric Deussing (DOD);  Kim Taylor (NIH); Chia-Wei Tsai (BARDA); Julianne Clifford (FDA)

Liaison Representatives: Richard Beigi (ACOG); Kathleen Neuzil (IDSA) ; James Campbell (AAP); Matthew Zahn (NACCHO)

Invited Consultants: Wendy Keitel; Arthur Friedlander; Phillip Pittman; Andy Pavia, Stacy Hall

CDC: William Bower, Lead
Anthrax Vaccine Work Group Activities

- Reconvened in March 2017
- Purpose
  - The US government stockpiles anthrax vaccine and antitoxin for postexposure prophylaxis (PEP) should there be a wide-area release of *Bacillus anthracis* spores
  - The work group considered the body of evidence since last review in 2010 for policy changes to optimize the use of anthrax vaccine for postexposure prophylaxis (PEP) following a wide-area release of *Bacillus anthracis* spores
  - The work group is also reviewing the body of evidence for use of anthrax antitoxin for PEP when no effective antimicrobials are available
Today’s session

- Informational session on new anthrax vaccine (AV7909) for postexposure prophylaxis

- Informational session on anthrax antitoxin for postexposure prophylaxis